CompletedNCT00566735
Galantamine or placebo for thinking and memory changes after ECT
About this title
Read the official source — NCT00566735Medication studyAges 18–90United StatesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 90 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 90 Years
- Official registry ID
- NCT00566735
- Official title
Show the full official title
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Razadyne and Placebo.
Who was this study for?
Listed age limits: 18 years to 90 years.
